Literature DB >> 26115516

Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar.

Thomas H P Draak1, Mariëlle H J Pruppers1, Sonja I van Nes2, Els K Vanhoutte3, Mayienne Bakkers1, Kenneth C Gorson4, W-Ludo Van der Pol5, Richard A Lewis6, Nicolette C Notermans5, Eduardo Nobile-Orazio7, Jean-Marc Léger8, Peter Y K Van den Bergh9, Giuseppe Lauria10, Vera Bril11, Hans Katzberg11, Michael P T Lunn12, Jean Pouget13, Anneke J van der Kooi14, Leonard H van den Berg5, Pieter A van Doorn2, David R Cornblath15, Angelika F Hahn16, Catharina G Faber1, Ingemar S J Merkies1,17.   

Abstract

The Jamar dynamometer and Vigorimeter have been used to assess grip strength in immune-mediated neuropathies, but have never been compared to each other. Therefore, we performed a comparison study between these two devices in patients with immune-mediated neuropathies. Grip strength data were collected in 102 cross-sectional stable and 163 longitudinal (new diagnoses or changing condition) patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), gammopathy-related polyneuropathy (MGUSP), and multifocal motor neuropathy (MMN). Stable patients were assessed twice (validity/reliability studies). Longitudinal patients were assessed 3-5 times during 1 year. Responsiveness comparison between the two tools was examined using combined anchor-/distribution-based minimum clinically important difference (MCID) techniques. Patients were asked to indicate their preference for the Jamar or Vigorimeter. Both tools correlated highly with each other (ρ = 0.86, p < 0.0001) and showed good intra-class correlation coefficients (Jamar [Right/Left hands]: ICC 0.997/0.96; Vigori: ICC 0.95/0.98). Meaningful changes were comparable between the two instruments, being higher in GBS compared to CIDP patients. In MGUSP/MMN poor responsiveness was seen. Significant more patients preferred the Vigorimeter. In conclusion, validity, reliability, and responsiveness aspects were comparable between the Jamar dynamometer and Vigorimeter. However, based on patients' preference, the Vigorimeter is recommended in future studies in immune-mediated neuropathies.
© 2015 Peripheral Nerve Society.

Entities:  

Keywords:  Jamar dynamometer; Vigorimeter; grip strength; responsiveness comparison

Mesh:

Year:  2015        PMID: 26115516     DOI: 10.1111/jns.12126

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  4 in total

Review 1.  Effect of Action Observation Therapy in the Rehabilitation of Neurologic and Musculoskeletal Conditions: A Systematic Review.

Authors:  Deirdre Ryan; Brona Fullen; Ebonie Rio; Ricardo Segurado; Diarmiad Stokes; Cliona O'Sullivan
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-01-27

2.  Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.

Authors:  Jeffrey A Allen; Mamatha Pasnoor; Mazen M Dimachkie; Senda Ajroud-Driss; Thomas H Brannagan; Albert A Cook; Timothy Walton; Mark B Fiecas; John T Kissel; Ingemar Merkies; Kenneth C Gorson; Richard A Lewis
Journal:  Neurology       Date:  2021-02-16       Impact factor: 9.910

3.  Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.

Authors:  Juliane Klehmet; Svenja Beutner; Sarah Hoffmann; Matthias Dornauer; Friedemann Paul; Ralf Reilmann; Alexander U Brandt; Andreas Meisel
Journal:  BMC Neurol       Date:  2019-06-08       Impact factor: 2.474

4.  Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial.

Authors:  Robin van Veen; Luuk Wieske; Ilse Lucke; Max E Adrichem; Ingemar S J Merkies; Ivo N van Schaik; Filip Eftimov
Journal:  J Peripher Nerv Syst       Date:  2022-05-25       Impact factor: 5.188

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.